AskAt Inc. (Headquarters: Nagoya; President: Akihiro Furuta) announced today that it has terminated its license agreement with Oxford Cannabinoid Technologies Ltd. (“OCT”) regarding AAT-730, a CB2 agonist.

The agreement, originally signed in September 2019, was terminated by AskAt due to a breach of contract by OCT.

We will seek a new partner to continue the development.